Patient Perspectives on Incretin-based Weight Loss Medications and Relationship with Demographic Factors

Overview

Journal Obes Sci Pract

Date 2024 Aug 7

PMID 39109182

Authors

Megan A McVay

Wendy S Moore

Francesca L Wilkins

Jalen R Jackson

Michael D Robinson

Affiliations

Soon will be listed here.

Abstract

Objective: Treatment of obesity has been transformed by the recent approval of incretin-based therapies for weight loss (e.g., glucagon-like peptide 1 agonist semaglutide), but little is known about patient perspectives on these medications.

Methods: Between December 2023 and March 2024, healthcare patients from an academic medical center in the Southeast United States with Body Mass Index ≥30 kg/m completed a cross-sectional online survey on attitudes toward incretin-based medications.

Results: Compared to patients with a bachelor's degree, those without a degree were less likely to be aware of incretin-based pharmacotherapies (96% vs. 78%) and to have discussed pharmacotherapies with a doctor (43% vs. 27%) but had greater interest in using these pharmacotherapies (4.3 vs. 4.7). These pharmacotherapy-related variables did not differ significantly according to gender, race, or financial security. Concerns about side effects, long-term health risks, and potential for weight regain were highly endorsed and were associated with lower interest in using incretin-based therapies and with some demographic factors. Patients reported high interest in lifestyle programs designed for individuals taking anti-obesity medications.

Conclusion: Demographic considerations, notably education level, should be factored into the strategy to promote equitable utilization of incretin-based therapies, particularly as their accessibility expands.

References

Garvey W, Mahle C, Bell T, Kushner R . Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists. Obes Sci Pract. 2024; 10(3):e756. PMC: 11069397. DOI: 10.1002/osp4.756. View

Xia Y, Kelton C, Guo J, Bian B, Heaton P . Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010. Obesity (Silver Spring). 2015; 23(8):1721-8. DOI: 10.1002/oby.21136. View

McCoy R, Van Houten H, Deng Y, Karaca Mandic P, Ross J, Montori V . Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019. JAMA Netw Open. 2021; 4(2):e2035792. PMC: 7851726. DOI: 10.1001/jamanetworkopen.2020.35792. View

Garvey W, Batterham R, Bhatta M, Buscemi S, Christensen L, Frias J . Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022; 28(10):2083-2091. PMC: 9556320. DOI: 10.1038/s41591-022-02026-4. View

Williams R, Barefoot J, Califf R, Haney T, Saunders W, Pryor D . Prognostic importance of social and economic resources among medically treated patients with angiographically documented coronary artery disease. JAMA. 1992; 267(4):520-4. View

Sarwer D, Gasoyan H, Bauerle Bass S, Spitzer J, Soans R, Rubin D . Role of weight bias and patient-physician communication in the underutilization of bariatric surgery. Surg Obes Relat Dis. 2021; 17(11):1926-1932. PMC: 8551024. DOI: 10.1016/j.soard.2021.07.013. View

Wilding J, Batterham R, Calanna S, Davies M, Van Gaal L, Lingvay I . Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021; 384(11):989-1002. DOI: 10.1056/NEJMoa2032183. View

Ali A, Khan M, Ortega D, Jaffery S, Lamerato L, Budzynska K . Prescription Patterns of Novel Antihyperglycemic Medications. J Am Board Fam Med. 2022; 35(2):255-264. DOI: 10.3122/jabfm.2022.02.210360. View

Wadden T, Bailey T, Billings L, Davies M, Frias J, Koroleva A . Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021; 325(14):1403-1413. PMC: 7905697. DOI: 10.1001/jama.2021.1831. View

10.

Kosiborod M, Abildstrom S, Borlaug B, Butler J, Rasmussen S, Davies M . Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023; 389(12):1069-1084. DOI: 10.1056/NEJMoa2306963. View

11.

Lamprea-Montealegre J, Madden E, Tummalapalli S, Peralta C, Neilands T, Garcia P . Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System. JAMA. 2022; 328(9):861-871. PMC: 9449794. DOI: 10.1001/jama.2022.13885. View

12.

Lincoff A, Brown-Frandsen K, Colhoun H, Deanfield J, Emerson S, Esbjerg S . Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023; 389(24):2221-2232. DOI: 10.1056/NEJMoa2307563. View

13.

Arterburn D, Tuzzio L, Anau J, Lewis C, Williams N, Courcoulas A . Identifying barriers to shared decision-making about bariatric surgery in two large health systems. Obesity (Silver Spring). 2023; 31(2):565-573. DOI: 10.1002/oby.23647. View

14.

Eberly L, Yang L, Essien U, Eneanya N, Julien H, Luo J . Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. JAMA Health Forum. 2022; 2(12):e214182. PMC: 8796881. DOI: 10.1001/jamahealthforum.2021.4182. View

15.

Claridy M, Czepiel K, Bajaj S, Stanford F . Treatment of Obesity: Pharmacotherapy Trends of Office-Based Visits in the United States From 2011 to 2016. Mayo Clin Proc. 2021; 96(12):2991-3000. PMC: 8649050. DOI: 10.1016/j.mayocp.2021.07.021. View

16.

Jastreboff A, Aronne L, Ahmad N, Wharton S, Connery L, Alves B . Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022; 387(3):205-216. DOI: 10.1056/NEJMoa2206038. View

17.

Balza J, Cusatis R, McDonnell S, Basir M, Flynn K . Effective questionnaire design: How to use cognitive interviews to refine questionnaire items. J Neonatal Perinatal Med. 2022; 15(2):345-349. PMC: 9524256. DOI: 10.3233/NPM-210848. View